editorial | Q871232 |
scholarly article | Q13442814 |
P50 | author | Erika Martinelli | Q90711351 |
P2093 | author name string | Fortunato Ciardiello | |
Teresa Troiani | |||
Stefania Napolitano | |||
P2860 | cites work | A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 |
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 | ||
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence | Q28071772 | ||
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer | Q28076490 | ||
EGFR antagonists in cancer treatment | Q29616740 | ||
Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study | Q47582754 | ||
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer | Q50066241 | ||
Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine | Q90097342 | ||
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer | Q90362927 | ||
Back to the Colorectal Cancer Consensus Molecular Subtype Future | Q91285027 | ||
HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer | Q92353853 | ||
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge | Q93270142 | ||
P433 | issue | 2 | |
P921 | main subject | colorectal cancer | Q188874 |
metastatic colon cancer | Q108566365 | ||
P577 | publication date | 2020-03-01 | |
P1433 | published in | ESMO Open | Q53951848 |
P1476 | title | Towards the era of precision medicine in metastatic colorectal cancer | |
P478 | volume | 5 |
Search more.